CRISPR Therapeutics Investors

27 investors on Angel Roster list CRISPR Therapeutics in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Series B and the largest groups are based in the United States, the United Kingdom and Switzerland.

Investors are matched on the company name in their portfolio, so companies that share the name CRISPR Therapeutics can appear together.

Investors listed
27
With verified email
33%
Most common stage
Series B
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 27 CRISPR Therapeutics investors

The most complete profiles first. Showing 27 of 27.

  • Brian AtwoodVerified

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsCybersecurityWomen Founded

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 63 more

    Verified email available

  • Ken HaasVerified

    Venture Capital, Advisor, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • andrew sinclairVerified

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Ali BehbahaniVerified

    Venture Capital, Private Equity Firm, Angel/Individual · United States

    Series BHealth CareE-commerceWomen FoundedEnterprise Software

    Portfolio: Adaptimmune, Monte Rosa Therapeutics, 858 Therapeutics, GOAT and 5 more

    Verified email available

  • Alexander MaywegVerified

    Venture Capital, Private Equity Firm · Switzerland

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 58 more

    Verified email available

  • Matthew FoyVerified

    Corporate Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Semprus BioSciences, Pulmocide, Syntaxin, CRISPR Therapeutics and 50 more

    Verified email available

  • Ron HuntVerified

    Venture Capital, Private Equity Firm · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Verified email available

  • Shelley ChuVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Tim HainesVerified

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Bali Muralidhar

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more

    Contact details available

  • Brian Gallagher, Jr.

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more

    Contact details available

  • Carlo Rizzuto

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 60 more

    Contact details available

  • Charles Warden

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 61 more

    Contact details available

  • Kurt von Emster

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareWomen FoundedInvestment ManagementLife Science

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Ross Jaffe

    Venture Capital, Investor · United States

    Series BHealth CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 59 more

    Contact details available

  • Vin Miles

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Beckie Robertson

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 58 more

    Contact details available

  • Bill Link

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 58 more

    Contact details available

  • Craig Slutzkin

    Venture Capital, Private Equity Firm · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Contact details available

  • Don Milder

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 58 more

    Contact details available

  • James Niedel

    Venture Capital, Private Equity Firm · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Contact details available

  • Jeffrey Ives

    Venture Capital · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Contact details available

  • John Heard

    Venture Capital, Private Equity Firm · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Paul Grayson

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Black Diamond Therapeutics, Kyras Therapeutics, CRISPR Therapeutics, Aligos Therapeutics and 58 more

    Contact details available

  • Rebecca Luse

    Venture Capital · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Contact details available

  • Sarah Shackelton

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Vijay Lathi

    Venture Capital, Private Equity Firm · United States

    Health CareCybersecurityMessagingWomen Founded

    Portfolio: iRhythm Technologies, Braeburn, Direct Flow Medical, Edgewise Therapeutics and 56 more

    Contact details available

By investment stage

By location

Related industries

Most-backed portfolio companies

Frequently asked questions

How many CRISPR Therapeutics investors are on Angel Roster?

Angel Roster lists 27 CRISPR Therapeutics investors. 9 of them (33%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (26), Private Equity Firms (13) and Advisor Investors (1). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do CRISPR Therapeutics investors invest in?

Among those that list a stage, the most common are Series B (8) and Seed (3).

Where are CRISPR Therapeutics investors based?

Most are based in the United States (20), the United Kingdom (6) and Switzerland (1).

Which companies have CRISPR Therapeutics investors backed?

The most-backed portfolio companies among them are Venatorx Pharmaceuticals (19), Nouscom (19), GenSight Biologics (19), Passage Bio (15) and Effector Therapeutics (11).

How do I contact CRISPR Therapeutics investors?

Create a free Angel Roster account to search and filter all 27, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.